Oxybutynin Chloride is an antispasmodic and anticholinergic medication. Effective for the treatment of a variety of bladder conditions, such as overactive bladder, detrusor instability, detrusor hyperreflexia, spasmodic bladder, unstable bladder, irritable bladder, incontinence and bladder spasms, the brand name for this medication is Ditropan XL. Ortho-McNeil Pharmaceutical Inc. markets oxybutynin chloride as Ditropan XL, with a patent expiration for this product on May 22, 2015. Oxybutynin chloride is in the class of drugs known as antimuscarinic or anticholinergic medications. By blocking specific receptors in the bladder, which are called muscarinic receptors, the bladder muscles are better able to relax, thus relieving symptoms like frequent and uncontrollable bladder contractions. The extended release tablets available contain either 5, 10, or 15 milligrams of oxybutynin chloride. The dose is designed to be taken once daily.
Also indicated for the treatment of pediatric patients ages 6 and older, oxybutynin chloride is effectual for children who may experience detrusor overactivity due to a neurological condition like Spina Bifida. The recommended dose for children is 5 milligrams to be taken once a day, at the same time each day. The dosage may be adjusted as needed, but the maximum dose is 20 milligrams per day. Adults who are dosed with oxybutynin chloride typically start at either 5 or 10 milligrams, to be taken once daily. Dosage changes may be made in 5 milligram jumps, preferably made at the same weekly interval or day. The maximum dose for an adult is 30 milligrams daily. Side effects of oxybutynin chloride include the possibility of headache, constipation, diarrhea, nausea, dry mouth, dizziness, rhinitis and urinary tract infections.
Clinical trials of oxybutynin chloride showed this medication to be well tolerated, safe and effective. Three initial studies of oxybutynin chloride were completed, alongside an open label study. There were 429 patients enrolled in three controlled studies, all of whom suffered from overactive bladder and incontinence episodes. The controlled studies found that oxybutynin chloride demonstrated superior efficacy when compared to a placebo for the reduction of incontinence episodes. Patients who were dosed with 15 milligrams of oxybutynin chloride daily saw a decrease in their episodes of incontinence, starting with 18.6 episodes a week and decreasing to 1.5 episodes a week.
LGM Pharma provides the API Oxybutynin Chloride CAS# 1508-65-2 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.